Market research
MWG.F InMed Pharmaceuticals Inc
F EUR Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 8M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- 0.93
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- CA4576377002
- Market cap
- 8M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- 0.93
About
About InMed Pharmaceuticals Inc
InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States. The company researches and develops cannabinoid-based pharmaceuticals products. Its product candidates include INM-901 for Alzheimer's disease, INM-089 for dry age-related macular degeneration, and INM-755, a cannabinol cream. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.
Research context
InMed Pharmaceuticals Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the MWG.F discussion.
5 years, 7 months ago
InMed Pharmaceuticals Inc is currently in a long term downtrend where the price is trading 19.2% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
InMed Pharmaceuticals Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 33.0% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 35.7% to $-2M since the same quarter in the previous year.
Based on the above factors, InMed Pharmaceuticals Inc gets an overall score of 3/5.